1. Scrip
  2. >>Business

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

 
• By Mandy Jackson, Ian Haydock, and Jung Won Shin

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Finance Watch

Venture capital investment in biopharmaceutical companies is booming in 2020. And while novel cancer and immuno-oncology programs continue to attract large sums, drug developers working on treatments for neurological diseases also are raising sizeable venture rounds. Among six companies with recently announced financings, Nura Bio Inc. launched with $73m in series A cash and Encoded Therapeutics Inc. closed a $135m series D round. 

Pitchbook and the National Venture Capital Association (NVCA) reported in their Venture Monitor report earlier this month that biopharma companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.